American Medical Association slams Supreme Court ruling on affirmative action, saying it 'undermines decades of progress'

Today the American Medical Association issued a scathing statement in response to the Supreme Court’s ruling against Harvard and the University of North Carolina’s affirmative action programs. 

The AMA stated that the decision will “undermine decades of progress” and “reverse gains made in the battle against health inequities.” 

On June 29, the court ruled that affirmative action programs, which allow colleges to consider an applicant’s race in the admissions process, violate the Equal Protection Clause of the Constitution. The decision effectively overturns a prior ruling from 2003 that enabled colleges to consider race in the application process as a means of promoting diversity in higher education. 

The AMA highlighted concerns with how the ruling could affect future medical school applicants. They cited published evidence demonstrating that diverse medical care teams improve patient outcomes, especially in marginalized populations. 

“This ruling restricts medical schools from considering race and ethnicity among the multiple factors in admissions policies and will translate into a less diverse physician workforce. Diversity is vital to healthcare, and this court ruling deals a serious blow to our goal of increasing medical career opportunities for historically marginalized and minoritized people,” the statement reads. 

Prior to the ruling, AMA filed an amicus brief, which was cited during the case, in support of Harvard and UNC. A recently established AMA policy highlights the importance of recruiting diverse talent from marginalized communities that have historically been underrepresented in the medical field. Achieving this, AMA stated, requires “more commitment to, investment in and support for” such communities. 

AMA stated that the ruling undermines the positive results those policies have rendered. 

“This ruling is bad for healthcare, bad for medicine, and undermines the health of our nation.” 

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel. 

Kit Crancer, RBMA board member, speaks with Radiology Business about key legislative developments on the Hill that will affect the specialty.